Tarsus制药公司首席执行官和内幕卖股票 但分析师还是推荐买"Buy" Tarsus Pharmaceuticals' CEO and insider sell stocks, but analysts still recommend a "Buy."

Tarsus制药公司是一家发展眼科护理治疗的生物制药公司,最近看到其首席执行官和一位内幕人员出售了大量股票。 Tarsus Pharmaceuticals, a biopharmaceutical firm developing eye care treatments, saw its CEO and an insider sell significant stock shares recently. 股票销售遵循公司开发XDEMVY的工作重点,这是治疗脑膜炎等眼疾的治疗方法。 The stock sales follow the company's focus on developing XDEMVY, a treatment for eye conditions like blepharitis. 尽管内部销售量如此,分析师仍保持“Buy”评级,目标价为63.67美元。 Despite these insider sales, analysts maintain a "Buy" rating with a target price of $63.67. 该公司报告了负面金融指标,但市场上限为19.2亿美元,主要由机构投资者所有。 The company reports negative financial metrics but has a market cap of $1.92 billion and is largely owned by institutional investors.